|
1
|
Boguski MS, Mandl KD and Sukhatme VP: Drug
discovery. Repurposing with a difference. Science. 324:1394–1395.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon
JH, Moon JO, Chung HY, Kim GY, Choi YH, Copple BL, et al: Aspirin
induces apoptosis in vitro and inhibits tumor growth of human
hepatocellular carcinoma cells in a nude mouse xenograft model. Int
J Oncol. 40:1298–1304. 2012.
|
|
4
|
Triscott J, Lee C, Hu K, Fotovati A, Berns
R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, et al: Disulfiram, a
drug widely used to control alcoholism, suppresses the self-renewal
of glioblastoma and over-rides resistance to temozolomide.
Oncotarget. 3:1112–1123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bashir MN: Epidemiology of prostate
cancer. Asian Pac J Cancer Prev. 16:5137–5141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karantanos T, Corn PG and Thompson TC:
Prostate cancer progression after androgen deprivation therapy:
Mechanisms of castrate resistance and novel therapeutic approaches.
Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barton BE, Karras JG, Murphy TF, Barton A
and Huang HF: Signal transducer and activator of transcription 3
(STAT3) activation in prostate cancer: Direct STAT3 inhibition
induces apoptosis in prostate cancer lines. Mol Cancer Ther.
3:11–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ni Z, Lou W, Leman ES and Gao AC:
Inhibition of constitutively activated Stat3 signaling pathway
suppresses growth of prostate cancer cells. Cancer Res.
60:1225–1228. 2000.PubMed/NCBI
|
|
9
|
Bishop JL, Thaper D and Zoubeidi A: The
multifaceted roles of STAT3 signaling in the progression of
prostate cancer. Cancers (Basel). 6:829–859. 2014. View Article : Google Scholar
|
|
10
|
Egolf A and Coffey BJ: Current
pharmacotherapeutic approaches for the treatment of Tourette
syndrome. Drugs Today (Barc). 50:159–179. 2014. View Article : Google Scholar
|
|
11
|
Taub RN and Baker MA: Treatment of
metastatic malignant melanoma with pimozide. Lancet. 1:6051979.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Strobl JS, Kirkwood KL, Lantz TK, Lewine
MA, Peterson VA and Worley JF III: Inhibition of human breast
cancer cell proliferation in tissue culture by the neuroleptic
agents pimozide and thioridazine. Cancer Res. 50:5399–5405.
1990.PubMed/NCBI
|
|
13
|
Nelson EA, Walker SR, Weisberg E,
Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo
L, Addorio MR, et al: The STAT5 inhibitor pimozide decreases
survival of chronic myelogenous leukemia cells resistant to kinase
inhibitors. Blood. 117:3421–3429. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nelson EA, Walker SR, Xiang M, Weisberg E,
Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais
M, et al: The STAT5 inhibitor pimozide displays efficacy in models
of acute myelogenous leukemia driven by FLT3 mutations. Genes
Cancer. 3:503–511. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Strobl JS, Melkoumian Z, Peterson VA and
Hylton H: The cell death response to gamma-radiation in MCF-7 cells
is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res
Treat. 51:83–95. 1998. View Article : Google Scholar
|
|
16
|
Chen JJ, Cai N, Chen GZ, Jia CC, Qiu DB,
Du C, Liu W, Yang Y, Long ZJ and Zhang Q: The neuroleptic drug
pimozide inhibits stem-like cell maintenance and tumorigenicity in
hepatocellular carcinoma. Oncotarget. May 27–2015.Epub ahead of
print.
|
|
17
|
Levina V, Marrangoni AM, DeMarco R,
Gorelik E and Lokshin AE: Drug-selected human lung cancer stem
cells: Cytokine network, tumorigenic and metastatic properties.
PLoS One. 3:e30772008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
19
|
Shodeinde AL and Barton BE: Potential use
of STAT3 inhibitors in targeted prostate cancer therapy: Future
prospects. Onco Targets Ther. 5:119–125. 2012.PubMed/NCBI
|
|
20
|
Guo Y, Xu F, Lu T, Duan Z and Zhang Z:
Interleukin-6 signaling pathway in targeted therapy for cancer.
Cancer Treat Rev. 38:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin D, Wyatt AW, Xue H, Wang Y, Dong X,
Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L, et al: High fidelity
patient-derived xenografts for accelerating prostate cancer
discovery and drug development. Cancer Res. 74:1272–1283. 2014.
View Article : Google Scholar
|
|
23
|
Lorenzo CR and Koo J: Pimozide in
dermatologic practice: A comprehensive review. Am J Clin Dermatol.
5:339–349. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seeman P: Atypical antipsychotics:
Mechanism of action. Can J Psychiatry. 47:27–38. 2002.PubMed/NCBI
|
|
25
|
Muscat R, Sampson D and Willner P:
Dopaminergic mechanism of imipramine action in an animal model of
depression. Biol Psychiatry. 28:223–230. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen X, Ji ZL and Chen YZ: TTD:
Therapeutic target database. Nucleic Acids Res. 30:412–415. 2002.
View Article : Google Scholar :
|
|
27
|
Jing N and Tweardy DJ: Targeting Stat3 in
cancer therapy. Anticancer Drugs. 16:601–607. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wendt MK, Balanis N, Carlin CR and
Schiemann WP: STAT3 and epithelial-mesenchymal transitions in
carcinomas. JAKSTAT. 3:e289752014.PubMed/NCBI
|
|
29
|
Teng Y, Ross JL and Cowell JK: The
involvement of JAK-STAT3 in cell motility, invasion, and
metastasis. JAKSTAT. 3:e280862014.PubMed/NCBI
|
|
30
|
Al Zaid Siddiquee K and Turkson J: STAT3
as a target for inducing apoptosis in solid and hematological
tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X, Crowe PJ, Goldstein D and Yang JL:
STAT3 inhibition, a novel approach to enhancing targeted therapy in
human cancers (Review). Int J Oncol. 41:1181–1191. 2012.PubMed/NCBI
|
|
32
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar
|
|
33
|
Gurbuz V, Konac E, Varol N, Yilmaz A,
Gurocak S, Menevse S and Sozen S: Effects of AG490 and S3I-201 on
regulation of the JAK/STAT3 signaling pathway in relation to
angiogenesis in TRAIL-resistant prostate cancer cells in vitro.
Oncol Lett. 7:755–763. 2014.PubMed/NCBI
|
|
34
|
Han Z, Wang X, Ma L, Chen L, Xiao M, Huang
L, Cao Y, Bai J, Ma D, Zhou J, et al: Inhibition of STAT3 signaling
targets both tumor-initiating and differentiated cell populations
in prostate cancer. Oncotarget. 5:8416–8428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao M, Jiang B and Gao FH: Small molecule
inhibitors of STAT3 for cancer therapy. Curr Med Chem.
18:4012–4018. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mankan AK and Greten FR: Inhibiting signal
transducer and activator of transcription 3: Rationality and
rationale design of inhibitors. Expert Opin Investig Drugs.
20:1263–1275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nelson EA, Sharma SV, Settleman J and
Frank DA: A chemical biology approach to developing STAT
inhibitors: Molecular strategies for accelerating clinical
translation. Oncotarget. 2:518–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
